GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Amylyx Pharmaceuticals Inc (NAS:AMLX) » Definitions » Preferred Stock

AMLX (Amylyx Pharmaceuticals) Preferred Stock : $0.0 Mil (As of Sep. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Amylyx Pharmaceuticals Preferred Stock?

Preferred stock is a special equity security that has properties of both equity and debt. Amylyx Pharmaceuticals's preferred stock for the quarter that ended in Sep. 2024 was $0.0 Mil.

The market value of preferred stock needs to be added to the market value of common stocks in the calculation of Enterprise Value. Amylyx Pharmaceuticals's Enterprise Value for the quarter that ended in Sep. 2024 was $-11.7 Mil.

In the calculation of book value, the par value of preferred stocks needs to subtracted from total equity. Amylyx Pharmaceuticals's Book Value per Share for the quarter that ended in Sep. 2024 was $2.86.

Dividends paid to preferred stocks need to be subtracted from net income in the calculation of Earnings per Share (Diluted). Amylyx Pharmaceuticals's Earnings per Share (Diluted) for the three months ended in Sep. 2024 was $-1.07.


Amylyx Pharmaceuticals Preferred Stock Historical Data

The historical data trend for Amylyx Pharmaceuticals's Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amylyx Pharmaceuticals Preferred Stock Chart

Amylyx Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Preferred Stock
- - - - -

Amylyx Pharmaceuticals Quarterly Data
Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Preferred Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Amylyx Pharmaceuticals Preferred Stock Calculation

Preferred Stock is a special equity security that has properties of both equity and debt. It is generally considered a hybrid instrument. Preferred stock is senior to common stock, but is subordinate to bonds in terms of claim or rights to their share of the assets of the company.

Preferred stock has priority over common stock in the payment of dividends and any payments received when a company liquidates.

Preferred stock comes in many forms. It can be:


Convertible or Non-Convertible
Cumulative or Non-Cumulative
Voting or Non-Voting
Callable or Non-Callable
Maturity Date or No Maturity Date

A preferred stock without a maturity date is called a perpetual preferred stock. These are relatively rare. A good example of perpetual preferred stock is the many series of Public Storage (PSA) preferred shares that trade on the New York Stock Exchange.

Before investing in preferred stock, it is important to know which of the above groups the stock belongs to. Is it convertible or non-convertible? Are dividends cumulative or non-cumulative?

It is also critical that an investor knows what bonds the company has in front of the preferred stock. Bondholders get paid first. So the decision to buy a preferred stock can be similar to the decision to buy a bond. But, remember, the preferred stock of a company with bonds is junior to those bonds.

Unless a preferred stock is convertible, the upside in a preferred stock investment is more limited than in a common stock investment. If a company doubles its earnings, it is usually under no more obligation to double the dividends paid to preferred shareholders than it is to double the interest paid to its bankers and bondholders.So preferred stock is very different from common stock.


Amylyx Pharmaceuticals  (NAS:AMLX) Preferred Stock Explanation

When a company needs capital but does not wish to issue debt, they may sell preferred stocks to investors.

For instance, during the financial crisis of 2008, Goldman Sachs (GS) issued a combination of preferred stock and common stock options for $5 billion of capital to Warren Buffett’s Berkshire Hathaway (BRK.A)(BRK.B). In this deal, Berkshire Hathaway paid $5 billion for 10% cumulative perpetual preferred stock and warrants to buy 43.5 million shares of Goldman Sachs at $115 a share. Goldman Sachs bought back the preferred in 2010. Guess how much money Warren Buffett made in this deal in two years? Read How Much Did Warren Buffett’s Berkshire Hathaway (BRK.B) Make on Its Goldman Sachs (GS) Preferred Stock?

1. The market value of Preferred Stocks needs to be added to the market value of common stocks in the calculation of enterprise value.

Amylyx Pharmaceuticals's Enterprise Value for the quarter that ended in Sep. 2024 is calculated as

2. In the calculation of Book Value, the par value of Preferred Stocks needs to subtracted from total equity.

Amylyx Pharmaceuticals's Book Value per Share for the quarter that ended in Sep. 2024 is calculated as

3. Dividends paid to Preferred Stocks need to be subtracted from net income in the calculation of earnings per share.

Amylyx Pharmaceuticals's Earnings per Share (Diluted) (EPS) for the three months ended in Sep. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Amylyx Pharmaceuticals Preferred Stock Related Terms

Thank you for viewing the detailed overview of Amylyx Pharmaceuticals's Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.


Amylyx Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
43 Thorndike Street, Cambridge, MA, USA, 02141
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder.
Executives
Joshua B Cohen director, officer: Co-Chief Executive Officer C/O AMYLYX PHARMACEUTICALS, INC., 43 THORNDIKE STREET, CAMBRIDGE MA 02141
Justin B. Klee director, officer: Co-Chief Executive Officer C/O AMYLYX PHARMACEUTICALS, INC., 43 THORNDIKE STREET, CAMBRIDGE MA 02141
Gina Mazzariello officer: Chief Legal Officer C/O AMYLYX PHARMACEUTICALS, INC., 43 THORNDIKE STREET, CAMBRIDGE MA 02141
James M Frates officer: Chief Financial Officer 88 SIDNEY ST, CAMBRIDGE MA 021394136
Karen Firestone director C/O AMYLYX PHARMACEUTICALS, INC., 43 THORNDIKE ST., CAMBRIDGE MA 02141
Milne George M Jr director
Daphne Quimi director C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Patrick D Yeramian officer: Chief Medical Officer 1815 PARKSIDE CIRCLE SOUTH, BOCA RATON FL 33486
Morningside Venture Investments Ltd 10 percent owner MCCARTHY LEGAL SERVICES, 1188 CENTRE STREET, NEWTON CENTRE MA 02459
Margaret Olinger officer: Chief Commercial Officer C/O AMYLYX PHARMACEUTICALS, INC., 43 THORNDIKE STREET, CAMBRIDGE MA 02141
Viking Global Investors Lp 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Dragsa 96 Llc 10 percent owner 55 RAILROAD AVE., GREENWICH CT 06830
Als Invest 1 B.v. 10 percent owner EERSTE WELERINGDWARSSTRAAL 54E, 1017 TP, AMSTERDAM P7 1017
Rose Sharon Shabet 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Paul R. Fonteyne director C/O RESTORBIO, INC., 501 BOYLSTON STREET SUITE 6102, BOSTON MA 02116